Business Context and Reporting Period
Company: Sanofi-Synthélabo (Sanofi)
Filing Date: January 26, 2004
Event: Announcement of a mixed public offer (cash and shares) to acquire Aventis.
Strategic Rationale: The transaction aims to create the number one pharmaceutical group in Europe and the third largest globally. The combined entity will feature a large portfolio of high-growth drugs, the third-largest R&D budget in the industry, and a strong presence in major world markets. Headquarters will remain in Paris.
Key Financial Metrics and Offer Terms
Offer Structure (Standard Entitlement):
- 5 Sanofi-Synthélabo shares and €69.00 in cash for every 6 Aventis shares.
- Implied value: €60.43 per Aventis share.
- Premium: 15.2% over the one-month average share price (ended Jan 21, 2004).
Pro Forma Combined Metrics (2002/2003 Data):
- Consolidated Sales (Core Business): €25 billion (Pro forma 2002).
- Worldwide Pharmaceutical Sales (LTM ended Sept 2003): €21.6 billion (Combined).
- R&D Expenditure (2002 Pro Forma): €4.3 billion.
- Employees: Approximately 103,171 (Combined).
- Key Products: 9 products with individual annual sales exceeding €500 million in 2003.
Financing: Sanofi has secured a credit facility of up to €12 billion to finance the cash component and refinance Aventis debt. Total cash consideration estimated at approximately €9.168 billion if 100% of shares are tendered.
Material Changes and Synergies
Expected Synergies:
- Total Annual Synergies: €1.6 billion (pre-tax), representing 6.4% of combined pro forma revenues.
- Timeline: 10% in 2004, 60% in 2005, and 100% from 2006.
- Restructuring Costs: Estimated at approximately €2 billion (pre-tax) over the first two years post-completion.
Financial Impact: The transaction is expected to be accretive to adjusted net income per share of the core business starting in 2004. Adjusted net income excludes purchase accounting charges, integration costs, and restructuring costs.
Guidance, Outlook, and Risks
Management Commentary: CEO Jean-François Dehecq stated the goal is to accelerate revenue growth, optimize product launches, enhance R&D productivity, and improve profitability. The deal is fully supported by principal shareholders Total and L'Oréal.
Conditions Precedent:
- Receipt of at least 50% of Aventis share capital and voting rights (fully diluted).
- Expiration of the waiting period under the US Hart-Scott Rodino Act (FTC approval).
- Approval by Sanofi-Synthélabo shareholders at an extraordinary general meeting.
Risks and Contingencies:
- Regulatory: The offer is subject to antitrust approvals in the US, Germany, and other jurisdictions.
- Integration: Synergies are estimates and may not be achieved in the projected timeframe or amounts.
- Market Volatility: The offer terms were set based on prices prior to market rumors on January 16-23, 2004.
- Divestitures: Sanofi intends to continue Aventis's program of divesting non-core assets and has begun selling interests in ARIXTRA and FRAXIPARINE.
Investor Verification Checklist
- Verify the final approval status of the US FTC and other regulatory bodies.
- Confirm the outcome of the Sanofi-Synthélabo extraordinary shareholder meeting regarding share issuance.
- Monitor the tender ratio to ensure the 81% stock / 19% cash aggregate limit is maintained.
- Review the upcoming Form F-4 registration statement for detailed risk factors and final prospectus terms.
- Track the progress of the divestiture of non-core assets (e.g., ARIXTRA, FRAXIPARINE) and the potential public offer for Hoechst AG shares.